This article is more than 5 years old. Information may no longer be current.

Seven updates in pediatric oncology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Childhood Cancer Awareness Month is observed in September.

In conjunction with the observance, HemOnc Today presents seven updates in pediatric oncology treatment.

• The novel antibody robatumumab (SCH717454, Merck) did not exhibit significant benefit as a single agent for patients with metastatic osteosarcoma. However, the agent showed promising long-term benefit with a tolerable safety profile in patients with metastatic Ewing sarcoma who responded to treatment. Read more.
• The deferral of postoperative radiotherapy in pediatric patients with medulloblastoma has increased in recent years. However, delaying radiotherapy appeared associated with poorer survival. Read more.
• The use of a double unit of unrelated cord blood did not significantly decrease transplantation failure in children and young adults with acute leukemia or myelodysplastic syndrome compared with use of a single unit with adequate cell dose. Read more.
• The FDA granted orphan drug designation to TK216 (Oncternal Therapeutics) for the treatment of Ewing sarcoma, a rare pediatric cancer comprised of highly malignant, undifferentiated tumors of bone. Read more.
• High-dose methotrexate appeared superior to Capizzi methotrexate without increasing toxicity in children and young adults with high-risk B-acute lymphoblastic leukemia. Read more.
• Novel advances in the use of checkpoint inhibitors — such as an anti–PD-1 or anti–PD-L1 — to treat pediatric leukemia may result in the ability to eliminate the use of chimeric antigen receptor T-cell therapy in that patient population in the future. Read more.
• The FDA granted rare pediatric disease designation to ABT-414 (AbbVie, Life Science Pharmaceuticals, Seattle Genetics) for the treatment of children with epidermal growth factor receptor–amplified diffuse intrinsic pontine glioma. Read more.